KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) shares are trading down nearly 2% this morning. The biotech company released a Form 8-K yesterday after the close, notifying the …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported financial results for …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, and its Pertussis academic …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that experimental results …
In a research report issued today, RBC Capital analyst Adnan Butt initiated coverage on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with an Outperform …
Analysts are weighing in on the Microbiome-focused company Synthetic Biologics Inc (NYSEMKT:SYN) and biopharmaceutical comapny Medivation Inc (NASDAQ:MDVN), with price targets ranging from 107% to 118% upside. …
In a research report issued today, BTIG analyst Tim Chiang reiterated a Buy rating on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with a $5 price …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that Raymond D. Stapleton, …
Synthetic Biologics Inc (NYSEMKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of …
